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OBJECTIVE — Treatmentguidelinesfordiabeteshavebecomeincreasinglystringentasmost
research shows that more aggressive intervention reduces the risks for complications. Commu-
nity data on the effect of these interventions are lacking.
RESEARCH DESIGN AND METHODS — Changes in the pharmacologic treatment of
diabetes, blood pressure, and cholesterol in adults with diabetes were analyzed in a longitudinal
population-basedstudyofAmericanIndiansfrom10independent3-yeartimeintervalsbetween
1975 and 2004. Trends in drug use were assessed by logistic regression models and trends in
glycemia, blood pressure, and cholesterol were assessed by linear models.
RESULTS — Among the study participants, the use of any medicine for the treatment of
diabetes increased from 53% in 1975–1978 to 67% in 2002–2004, Ptrend  0.0001. The use of
insulin as a single agent declined, and the use of combinations of insulin and oral agents
increased.In1990–1992,23%ofsubjectshadanA1C7%andby2002–2004,theproportion
had increased to 33%, Ptrend  0.0001. The use of anti-hypertensive medicine increased from
21% in 1975–1977 to 58% in 2002–2004, Ptrend  0.0001, coincident with a decline in mean
systolic blood pressure from 137 mmHg in 1975–1977 to 123 mmHg in 2002–2004, Ptrend 
0.0001. The use of lipid-lowering medicine also increased with an accompanying increase in
HDL and a decrease in non-HDL cholesterol concentration.
CONCLUSIONS — Majorchangesincommunitytreatmentpatternsfordiabetesandrelated
conditions coincided with improvements in glycemia, blood pressure, and cholesterol.
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T
here have been many revisions over
time in the guidelines developed for
the care of diabetic patients (1).
Large clinical trials such as the Diabetes
Control and Complications Trial (DCCT)
and the UK Prospective Diabetes Study
(UKPDS) have shown the importance of
tight glycemic control and lower blood
pressure for the prevention of complica-
tions in subjects with diabetes (2,3). Fur-
thermore, the proliferation of new anti-
hyperglycemic drugs (such as metformin
and the thiazolidinediones) and insulin
analogues has led to greater use of com-
bination therapy with a wider variety of
agents. New and more potent medicines
for blood pressure and lipid management
are also now more widely available. The
targets set for blood pressure and choles-
terol are lower for people with diabetes
than for those without (1,4). Efforts to
achieve these targets may be enhanced by
greater use of more efﬁcacious medicines
and ultimately may lead to signiﬁcant im-
provements in care.
The Pima Indians of central Arizona
have an extraordinarily high prevalence
oftype2diabetesandhaveparticipatedin
a longitudinal study of health for over 40
years (5). The aim of the current study
was to examine changes in medicine use
over 30 years in diabetic Pima Indians
who participated in this longitudinal
studyandtodetermineifchangesintreat-
ment corresponded with changes in gly-
cemia, blood pressure, and cholesterol.
RESEARCH DESIGN AND
METHODS— Individuals over 5
years of age who resided in a deﬁned area
of the Gila River Indian Community were
invited to participate in research exami-
nations every 2 years, regardless of their
health. Primary medical care for commu-
nity residents was provided separately
from the research examinations, except
when clinically relevant test results (labo-
ratory, physical examination, or other)
from the research examinations, includ-
ing new diagnoses of diabetes, were re-
portedtotheparticipantsandtheirhealth
care providers and appropriate referrals
weremade.Diabeteswasdiagnosedatthe
research examinations by World Health
Organization (WHO) criteria (6) if the
plasma glucose concentration 2 h after a
75-goralglucosetolerancetestwas200
mg/dl or if a diagnosis was made during
routineclinicalcare.Ateachexamination,
blood was also drawn after an overnight
fast for measurement of total cholesterol,
A1C, and, since 1992, for HDL choles-
terol and triglycerides. Subjects were
weighed while dressed in light clothing
and no shoes, and height was measured.
Blood pressure was measured at the ﬁrst
and fourth Korotkoff sounds with the
subject supine.
Plasmaglucoseconcentrationwasmea-
sured using the Technicon AutoAnalyzer
between 1975 and October 1991 and since
then by the hexokinase method. A1C was
measured by high-performance liquid
chromatography (HPLC) (Bio-Rad MDMS)
from 1989 until 2000 and thereafter by
HPLC (Tosoh A1c 2.2 Plus). A formula de-
rived from duplicate analyses using both
methods was used to convert the newer as-
say to the older assay, A1C old method 
0.2792  (1.0066  HbA1c new method).
Total cholesterol was measured until April
1992 by the ferric chloride/acetic acid-
sulfuric acid technique (Technicon Auto-
Analyzer) and thereafter by the enzymatic
method,whichwasalsousedformeasuring
HDL cholesterol.
A questionnaire was used to record
current medicine use. Prior to April
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broad categories only (e.g., anti-
hypertensive), but since April 1992
medicines were recorded by name and
only by type when more speciﬁc infor-
mation was unavailable.
The present analysis included all dia-
betic subjects over 18 years of age who
hadresearchexaminationsbetweenJanu-
ary 1975 and December 2004 and were
not pregnant at the time of examination.
Datafromexaminationsatwhichdiabetes
was ﬁrst diagnosed were not analyzed,
since the subjects had not yet received di-
abetes management at these examina-
tions. The investigators deﬁned 10
independent 3-year time periods. Sub-
jects could be included in multiple time
periods. When a subject had more than
one examination during a time period,
only the examination closest to the mid-
point of that time period was included.
The 3-year time periods were selected to
minimize the loss of information due to
the exclusion of data from repeat exami-
nations within the same period and to be
of sufﬁcient duration that reliable preva-
lence estimates could be made within
eachperiod.Variableswithskeweddistri-
bution (total cholesterol, HDL choles-
terol, non-HDL cholesterol, and
triglycerides) were log transformed for
analysis.
For continuous variables, relation-
ship with time period was examined by
linear regression. A numeric variable was
used to represent time periods in sequen-
tial order and the resultant P value was
taken as the test for secular trend (Ptrend).
For dichotomous variables, time trends
were assessed using logistic regression.
Because observations within an individ-
ual are not independent of one another,
an assumption of conventional regression
methods, both linear and logistic models,
wereﬁtwithgeneralizedestimatingequa-
tions that allow for lack of independence
among observations (PROC GENMOD,
SAS). Statistical signiﬁcance was assessed
with the empirical estimate of the stan-
dard error.
RESULTS— During the study, 2,019
diabetic individuals (1,218 women, 801
men) attended examinations. Of the par-
ticipants, 58% (n  1,173) attended dur-
ing only 1 or 2 time periods, whereas 1%
(n  18) attended examinations in 9
time periods. More people attended ex-
aminations in the ﬁnal time period (n 
775) than in earlier periods in keeping
with an increase in population size and
overall clinic attendance. Table 1 shows
clinical characteristics of the participants
by time period. Mean age of the attendees
declined over the course of the study,
whereas mean duration of diabetes in-
creased. There was a trend toward higher
BMIs for later time periods. The propor-
tion of clinic attendees with diabetes was
steady throughout the study period.
Diabetes treatment
Treatment for diabetes was categorized as
oral agents only, insulin only, and com-
bined oral agents and insulin. More re-
cently approved diabetes drugs, such as
exenatide or oral dipeptdyl peptidase-IV
inhibitors, were not used during this
study period. Over the course of the
study, the proportion of subjects receiv-
ing medicine for diabetes increased from
53% in 1975–1977 to 67% in 2002–
2004. Figure 1A shows changes in the
prevalenceofthedifferentmodesoftreat-
ment. The use of combined oral agents
and insulin increased from 1% in
1993–1995, the ﬁrst time period for
which accurate data are available, to
15.9% in the ﬁnal time period (Ptrend 
0.0001, adjusted for age, sex, and diabe-
tes duration). The increased use of multi-
ple agents was accompanied by a fall in
the use of insulin alone from 20% in
1993–1995to8%in2002–2004(Ptrend
0.0001).
Data for individual drug use were
available in the ﬁnal four time periods.
The prevalence of sulfonylurea use did
not change, but their use as single agents
declined. The use of metformin and thia-
zolidinediones increased, both in total
use and as single agents (Table 2).
Glycemia was assessed throughout
the study with fasting plasma glucose
and, since 1989, with A1C. Figure 1A
shows a downward trend for fasting glu-
cose with a difference in mean glucose
between successive time periods of
4.91 mg/dl (Ptrend  0.0001, adjusted
for age, sex, and diabetes duration). A
similartrendoccurredforA1Cforthelast
ﬁve time periods (means  SD 9.2% 
2.4, 9.4%  2.4, 8.8%  2.5, 8.5% 
2.4,and8.2%2.3,respectively),witha
difference in mean A1C between succes-
sive time periods of 0.319% (Ptrend 
0.0001, adjusted for age, sex, and diabe-
tesduration).Agreaterproportionofsub-
jectsreachedthegoalofanA1C7.0%in
the last two time periods than in earlier
time periods, and this was accompanied
by a reduction in the percentage of sub-
jects with an A1C 10%. The proportion
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betes while having an A1C 7% fell
throughoutthestudyfrom26%in1990–
1992 to 16% in 2002–2004.
Blood pressure
Fig. 1B illustrates the increasing use of
anti-hypertensive medicines, which rose
from21%in1975–1977to58%in2002–
2004 (Ptrend  0.0001, adjusted for age,
sex, and diabetes duration). Since 1993,
the use of ACE inhibitors and angiotensin
receptor blockers (ARBs) has increased
relative to other categories of anti-
hypertensive medicines. ACE inhibitors
and ARBs were used by 22% of individu-
als in 1993–1995 and by 48% of individ-
uals in 2002–2004. In 1993–1995,
diuretics, -blockers, and calcium chan-
nel blockers were used by 6, 2, and 4% of
participants, respectively; whereas in
2002–2004 the corresponding numbers
were16,7,and12%.In1993–1995,80%
of subjects taking anti-hypertensive
agents used only a single medicine,
whereas by 2002–04 only 59% of sub-
jectsdidsoand5%reportedusingfouror
more medicines for blood pressure con-
trol. The trends for use of all categories of
anti-hypertensive medicines were posi-
tive and statistically signiﬁcant, Ptrend 
0.0001, after adjustment for age, sex, and
diabetes duration.
Mean systolic (sBP) and diastolic
blood pressure (dBP) were highest in the
ﬁrsttimeperiodanddeclinedthroughout
the 1970s and early 1980s. Both pres-
sures increased again in the late 1980s,
followed by a further decline in the
1990s. Although the use of anti-
hypertensive agents increased after the
initialtimeperiod,therewasnoreduction
in use coinciding with the climb in mean
sBP in the early 1990s. The percentage of
subjects who met the current American
Diabetes Association (ADA) goal of a
blood pressure 130/80 was highest in
1981–1983 (52%), then decreased to a
low of 34% in 1987–1989, and returned
to 52% in the ﬁnal two time periods. In
1975–1977, 56% of subjects had a blood
pressure 	130/80 and were using no anti-
hypertensive medicines, whereas in 2002–
2004 the proportion of hypertensive
subjects not receiving anti-hypertensive
medicines was 18%. Overall, there was a
downward trend over time for mean sBP of
14 mmHg between 1975–1977 and 2002–
2004 (Ptrend  0.0014) and mean dBP of 7
mmHg (Ptrend  0.0001) after adjustment
for age, sex and diabetes duration.
Lipids
Data for lipid-lowering medicines are
only available for the ﬁnal four time peri-
ods. Only 1% of subjects reported the use
of lipid-lowering medicines in both the
1993–1995 and 1996–1998 time peri-
ods, and the proportion increased to 14%
in the ﬁnal time period (Ptrend  0.0001,
adjusted for age, sex, and diabetes dura-
tion); 88% of the drugs taken for lipid
lowering were statins (Fig. 1C).
Total cholesterol concentration var-
ied throughout the study with the highest
geometric mean value of 185 mg/dl in
1987–1989 and the lowest of 175 mg/dl
in 1975–1977, but the variation was not
statistically signiﬁcant. Likewise the per-
centage of subjects meeting the ADA
guidelines of total cholesterol 200
mg/dl was unchanged. However, al-
though 34% of subjects had cholesterol
concentrations 200 mg/dl and were not
receiving treatment in 1993–1995, the
proportion of those not receiving treat-
ment declined to 23% by 2002–2004,
and the percentage of subjects reaching
their goals while on treatment increased
from0.3to9%overthesametimeperiod.
Since 1989, subfractions of choles-
terolweremeasuredandrevealedarisein
HDL cholesterol and a fall in the non-
HDL cholesterolfraction(Fig.1C)coincid-
ing with the increased use of cholesterol-
lowering agents. Serum triglyceride
concentrations were unchanged over this
time period.
Goals
Speciﬁc targets are advised for patients
withdiabetesconcerningglycemia,blood
pressure, and cholesterol. Using the tar-
gets available at the close of the study,
goals for treatment were A1C 7%, sBP
130 mmHg, dBP 80 mmHg (1), and
total cholesterol 200 mg/dl (7). The
proportion of patients meeting all three
goals increased from 7.2% in 1990–1992
to 15.7% in 2002–2004 (Ptrend 0.0001,
adjusted for age, sex, and diabetes dura-
tion). Female sex, younger age, and
shorter duration of diabetes—but not
BMI—were signiﬁcantly associated with
reaching all goals (P  0.05, adjusted for
time period).
CONCLUSIONS— Majorchangesin
the treatment of diabetes and related con-
ditions have occurred in the Gila River
IndianCommunityoverthepast30years.
These changes coincide with signiﬁcant
improvements in glycemia, blood pres-
sure, and serum cholesterol concentra-
tionandwithadeclineintheincidenceof
kidney failure (8). The extent to which
improvements in glycemia, blood pres-
sure,andlipidshaveinﬂuencedincidence
of diabetic complications in the commu-
nity, however, cannot be determined
from an observational study.
The number of new classes of drugs
availabletotreatdiabetes,bloodpressure,
and cholesterol has increased in recent
years. Drugs to lower cholesterol came
into common use in the community only
in the last decade, and the majority of
drugsprescribedforthispurposewerest-
atins. Increased use of all major classes of
blood pressure agents, including estab-
lishedclasses,wasalsoobserved,suggest-
ing that increased use of medicines in
recent years reﬂects not just use of newer
drugsbutanefforttomeetmorestringent
treatment targets. In the most recent time
period, 15.7% of subjects met ADA goals
for glycemic control, blood pressure, and
total cholesterol; over twice the preva-
lence of 7.3% among diabetic subjects in
the National Health and Nutrition Exam-
ination Survey (NHANES) from 1999–
2003 (9). These ﬁndings are consistent
with a race/ethnicity comparison of mea-
sures of diabetes control in participants at
enrollment in the Look AHEAD (Action
for Health in Diabetes) clinical trial of
adultswithtype2diabetes.AmongAmer-
ican Indians in that study (some of whom
are from this community), 12.2% met the
goals of A1C 7%, sBP 130 mmHg,
dBP 80 mmHg, and LDL cholesterol
100 mg/dl. This percentage was higher
than among white, African American, or
Hispanic participants (10).
Indian Health Service (IHS) audit
data show a decline in mean A1C from
8.9% in 1995 to 7.9% in 2001 (11), con-
sistent with the decline in A1C in our
study, although the mean levels at both
time periods in our study were higher.
The IHS also reported greater improve-
ments in dBP, total cholesterol, and triglyc-
erides over this time period than in our
study. However, mean values were all
higher than in the present population. This
ﬁnding may reﬂect demographic differ-
ences because the IHS audit participants
were on average older and had a shorter
mean duration of diabetes than the partici-
pants in our study. Moreover, IHS audit
data are gathered from audited medical
records in which dates of diagnosis are
likely not as accurate and laboratory mea-
surements not as uniform as in our study.
Other population studies have re-
ported changes in treatment patterns for
Looker and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 11, NOVEMBER 2010 2385Figure1—Trendsintreatmentovertime.A:Diabetestreatmentbycategoryovertimeandmeanfastingglucoseovertime.Fortimeperiodspriorto1993,
combined use of oral agents and insulin was not recorded separately but included as insulin use. After 1993, data were available to show combined insulin
and oral agent use. This is shown as oof the insulin use column. Trend for oral agent only use, P0.0001. Trend for insulin only use, P0.0001. Trend
forcombinedoralagentsandinsulinuse,P0.0001.Trendformeanfastingglucose,change4.9mg/dlper3-yeartimeperiod,P0.0001.Alltrends
adjustedforage,sex,anddiabetesduration.B:Anti-hypertensiveuseandmeansBPanddBPovertime.Trendforanti-hypertensiveagentuse, P0.0001.
Trend for mean sBP parameter estimate  0.37 mmHg per 3-year time period, P  0.0014. Trend for mean dBP parameter estimate  0.37 mmHg,
P0.0001. All trends adjusted for age, sex, and diabetes duration. C: Lipid-lowering medicine use and geometric mean total, HDL, non-HDL cholesterol,
and triglycerides over time. Trend for lipid-lowering agent use, P0.0001. Trend for total cholesterol, change 0.0004 mg/dl, P0.77. Trend for HDL
cholesterol, change  0.051 mg/dl, per 3-year time period 0.0001. Trend for non-HDL cholesterol, change  0.046 mg/dl, P  0.0001. Trend for
triglycerides, change  0.015 mg/dl, P  0.16. All trends adjusted for age, sex, and diabetes duration.
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ids (9), and outcome measures, particu-
larly over the last decade. A shift away
from single agent insulin use has been re-
ported, along with increased use of hypo-
glycemic medicine (oral or insulin),
although most studies do not report im-
provements in glycemic control as mea-
sured by A1C (9). Increases in the use of
anti-hypertensive medicines, particularly
ACE inhibitors, however, are associated
with reductions in mean blood pressure
(9,10). The use of lipid-lowering drugs is
increasing and, in some studies, this in-
crease is accompanied by a fall in both
total cholesterol and triglycerides (9).
While there was a trend toward lower
blood pressure over time in the present
study, the decline was not linear. What
caused the earlier decline and rise is un-
clear. The increase in anti-hypertensive
medicine use in the last 15 years is more
marked and is associated with a fall in
blood pressure from 1990 to 1992, re-
turning to the lower levels seen earlier in
the study when anti-hypertensive medi-
cine was rarely used. The increased use of
anti-hypertensivemedicationmaybeare-
sponse to increased blood pressure, but it
may also be due to increased use of such
agentstotreatincipientdiabeticrenaldis-
ease. Our data do not permit us to distin-
guish between these two indications.
Figure 1—Continued.
Table 2—Prevalence of antidiabetic oral agent use by type: Gila River Indian Community, 1993–2004
1993–1995 1996–1998 1999–2001 2002–2004 P trend
n 623 464 575 775
Sulfonylureas Any use 254 (40.8%) 166 (35.8%) 213 (37.0%) 299 (38.6%) 0.93
Alone 254 (40.8%) 136 (29.3%) 102 (17.7%) 90 (11.6%) 0.0001
Metformin Any use 0 (0%) 30 (6.5%) 144 (25.0%) 287 (37.0%) 0.0001
Alone 0 (0%) 1 (0.2%) 23 (4.0%) 73 (9.4%) 0.0001
Thiazolidinediones Any use 0 (0%) 5 (1.1%) 46 (8.0%) 154 (19.9%) 0.0001
Alone 0 (0%) 0 (0%) 1 (0.2%) 2 (0.3%) 0.06
Data are number with percentages of all subjects in each time period in parentheses. “Any use” indicates all subjects reporting use of the drug and “Alone”indicates
subjectswhoaretakingthedrugastheironlytherapyfordiabetes.Oddsratiosaretheoddsratiospertimeperiodadjustedforage,sex,anddiabetesduration.Pvalue
for trend adjusted for age, sex, and diabetes duration.
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mia, blood pressure, and cholesterol frac-
tions, BMI increased throughout the
study. This increase may simply reﬂect
the increasing trend for BMI seen in the
general population (9), but it could also
be linked to the medicines used to treat
diabetes (12) and to the improvements in
glycemic control (3). IHS audit data show
an increase in mean BMI in diabetic
American Indians between 1995 and
2004 (13), and NHANES reported an in-
crease in obesity among diabetic subjects
between 1988–1994 and 1999–2000
without any overall improvement in gly-
cemia (9).
Along with changes in available med-
icinesandtreatmentgoals,therehavealso
been changes in the diagnostic criteria for
diabetes that may inﬂuence our ﬁndings.
In 1985, WHO published new criteria for
the diagnosis of diabetes, advocating di-
agnostic cut points of 140 mg/dl for
fasting glucose and 200 mg/dl for 2-h
glucose (6). In 1997, ADA proposed a
move away from the oral glucose toler-
ance test to a reliance on fasting glucose,
using the lower cut point of 126 mg/dl
(14). WHO also lowered the fasting cut
point to 126 mg/dl but continues to ad-
vocate for the 2-h glucose measurement
(15). (More recent proposals to base the
diagnosis of diabetes on A1C occurred af-
ter the present study [16,17].) Through-
out this study, we used the 2-h glucose
200 mg/dl to diagnose diabetes. Not all
subjects, however, are diagnosed in the
research setting; some are diagnosed as
part of routine medical care. Therefore,
differencesindiagnosticcriteriamayhave
occurred over the course of the study.
When subjects were divided according to
method of diagnosis, those diagnosed on
the basis of a 2-h postload glucose of
200 mg/dl had lower mean fasting glu-
cose and A1C than those diagnosed on
clinical grounds alone.
The DCCT showed the importance of
tight glycemic control for the prevention
of microvascular complications in sub-
jectswithtype1diabetes(2),andtheUK-
PDS reported similar ﬁndings in type 2
diabetes (3). However, overly intensive
glycemic control in patients with long-
standing type 2 diabetes may also have
risks. Three recent clinical trials that
sought to reduce the target A1C to levels
below 7% (i.e., A1C 6–6.5%), found
no beneﬁt on cardiovascular outcomes
andone,theACCORD(ActiontoControl
Cardiovascular Risk in Diabetes) trial,
found higher death and cardiovascular
event rates with more aggressive attempts
to normalize blood glucose (18–20).
Each of these recent trials also reported a
signiﬁcantly increased risk of severe hy-
poglycemia in the groups with the lower
A1C goals. As blood pressure control is
important for reducing both renal and
cardiovascular complications (21), lower
goalsforbloodpressureareadvocatedfor
peoplewithdiabetes(1,4).Thebeneﬁtsof
lowering blood pressure and lipids, how-
ever, appear to be limited, as recently re-
ported by the ACCORD clinical trial
(22,23).Additionally,inordertoreduce
the high risk of cardiovascular disease
in people with diabetes (24), a greater
use of aspirin (1) has been encouraged.
We did not report data on aspirin use in
the present study since data on aspirin
use may be less accurate than data on
other medicines because aspirin is
nonprescription.
The changes reported in this study
could represent, in part, a change in the
research clinic attendance pattern as op-
posed to a change in actual practice if, for
instance, the research clinic attendees
have become more likely to attend hospi-
tal clinics or have fewer complications of
diabetes than those who do not attend
clinics. However, neither the recruitment
policy for the study clinic nor the propor-
tion of attendees with diagnosed diabetes
at the clinic changed over the course of
the study. The mean age of clinic attend-
ees with diabetes and the mean age at on-
set of diabetes were younger in the more
recenttimeperiodsinkeepingwithashift
to an onset of diabetes at younger ages
(8,25). Medicine use was assessed by self-
report rather than from pharmacy
records. This approach may have led to
the underreporting of medicines, but it
may also have reduced the likelihood that
prescribed but untaken medicines were
recorded.
In a recent 30-year period, the goals
for treatment and the medicines available
to meet those goals have changed consid-
erably. The present study indicates that
efforts to meet ADA treatment goals for
the control of glycemia, blood pressure,
and cholesterol have met with some suc-
cess since the prevalence of attaining
these goals was over two times as high in
diabetic Pima Indians in 2002–2004 as in
1990–1992. These improvements have
beenaccompaniedbyanincreaseinmean
BMI. Nevertheless, improvements in the
otherparameterssuggestthatmembersof
this community have beneﬁted substan-
tially from progress in diabetes care over
the last three decades.
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